Shanghai Yizhong Pharmaceutical Co Ltd (688091) - Total Assets
Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) holds total assets worth CN¥1.54 Billion CNY (≈ $225.89 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 688091 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Shanghai Yizhong Pharmaceutical Co Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 688091 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Shanghai Yizhong Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Yizhong Pharmaceutical Co Ltd's total assets of CN¥1.54 Billion consist of 53.6% current assets and 46.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 44.5% |
| Accounts Receivable | CN¥54.45 Million | 3.8% |
| Inventory | CN¥45.17 Million | 3.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥8.36 Million | 0.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688091 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Yizhong Pharmaceutical Co Ltd's current assets represent 53.6% of total assets in 2024, an increase from 48.3% in 2017.
- Cash Position: Cash and equivalents constituted 44.5% of total assets in 2024, up from 1.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 3.8% of total assets.
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shanghai Yizhong Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Shanghai Yizhong Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.67 | 18.01 | 24.15 |
| Quick Ratio | 7.84 | 17.37 | 23.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥610.92 Million | CN¥798.86 Million | CN¥125.34 Million |
Shanghai Yizhong Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Yizhong Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.43 |
| Latest Market Cap to Assets Ratio | 0.85 |
| Asset Growth Rate (YoY) | -8.0% |
| Total Assets | CN¥1.45 Billion |
| Market Capitalization | $1.23 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Shanghai Yizhong Pharmaceutical Co Ltd's assets close to their book value (0.85x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Shanghai Yizhong Pharmaceutical Co Ltd's assets decreased by 8.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total assets of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.45 Billion ≈ $211.89 Million |
-7.97% |
| 2023-12-31 | CN¥1.57 Billion ≈ $230.23 Million |
+16.15% |
| 2022-12-31 | CN¥1.35 Billion ≈ $198.22 Million |
+12.83% |
| 2021-12-31 | CN¥1.20 Billion ≈ $175.68 Million |
+363.88% |
| 2020-12-31 | CN¥258.81 Million ≈ $37.87 Million |
-6.77% |
| 2019-12-31 | CN¥277.62 Million ≈ $40.62 Million |
+21.06% |
| 2018-12-31 | CN¥229.33 Million ≈ $33.56 Million |
+7.29% |
| 2017-12-31 | CN¥213.74 Million ≈ $31.28 Million |
-- |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more